2 active not recruiting, 2 completed, 1 recruiting, 1 terminated. 6 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Active not recruiting 2, Completed 2, Recruiting 1, Terminated 1 |
Follow AL Amyloidosis: new trials by email Literature Review of AL Amyloidosis trials Research Report on AL Amyloidosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis Autologous Hematopoietic Stem Cell Transplantation, Biopsy, Biospecimen Collection - AL Amyloidosis | Phase 3 | Recruiting | SWOG Cancer Research Network | 338 | 2024-07-01 | 2026-05-06 |
| Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis [18F]florbetaben - Cardiac Amyloidosis, AL Amyloidosis | Phase 3 | Completed | Lantheus Germany GmbH | 244 | 2023-01-13 | 2026-10-26 |
| A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES) CAEL-101, Placebo, cyclophosphamide, bortezomib, and dexamethasone (CyBorD) regimen - AL Amyloidosis | Phase 3 | Active not recruiting | Alexion Pharmaceuticals, Inc. | 281 | 2020-11-03 | 2026-06-17 |
| A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES) CAEL-101, Placebo, cyclophosphamide, bortezomib, and Dexamethasone (CyBorD) regimen - AL Amyloidosis | Phase 3 | Active not recruiting | Alexion Pharmaceuticals, Inc. | 125 | 2020-08-25 | 2026-07-02 |
| Trial of High Dose Melphalan/Stem Cell Transplant With or Without Bortezomib Bortezomib, Melphalan, Neupogen - AL Amyloidosis | Phase 3 | Terminated | Boston Medical Center | 3 | 2015-06-01 | 2018-09-10 |
| A Trial for Systemic Light-chain (AL) Amyloidosis BMDex - AL Amyloidosis | Phase 3 | Completed | European Myeloma Network B.V. | 110 | 2011-01-01 | 2017-03-10 |
Immunoglobulin Light-chain Amyloidosis (6) · Paraproteinemias (2) · Amyloid Neuropathies, Familial (1) · Amyloidosis (1)
Immune System Diseases (6) · Immunoproliferative Disorders (6) · Lymphoproliferative Disorders (6) · Metabolic Diseases (6) · Neoplasms (6) · Neoplasms by Histologic Type (6) · Neoplasms, Plasma Cell (6) · Nutritional and Metabolic Diseases (6) · Proteostasis Deficiencies (6) · Amyloidosis (5) · Paraproteinemias (4) · Blood Protein Disorders (2) · Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Amyloid Neuropathies (1)
Bortezomib (4) · Cyclophosphamide (3) · Dexamethasone (3) · Melphalan (3) · Clinical Protocols (2) · 4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene (1) · Biopsy (1) · Blood Component Removal (1) · Calcium Dobesilate (1) · Filgrastim (1) · Granulocyte Colony-Stimulating Factor (1) · Magnetic Resonance Spectroscopy (1) · Specimen Handling (1) · Stem Cell Transplantation (1) · auricularum (1)
Alexion Pharmaceuticals, Inc. (2) · Boston Medical Center (1) · European Myeloma Network B.V. (1) · Lantheus Germany GmbH (1) · SWOG Cancer Research Network (1)
United States (5) · Germany (3) · Italy (3) · Spain (3) · United Kingdom (3) · Australia (2) · Austria (2) · Belgium (2) · Brazil (2) · Canada (2) · China (2) · Czechia (2) · France (2) · Greece (2) · Israel (2)
Scott Swenson, MD (2) · Andrew Stephens, MD, PhD (1) · Patrick A Hagen (1) · Vaishali Sanchorawala, MD (1)
PMID 42212672, PMID 20085941, PMID 32730181
U10CA180888 (1)